Affiliated Hospital of Jiangsu University
Affiliated Hospital of Jiangsu University
Explore linked clinical trials.7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating a Text-Prompt AI Assistant for Chest CT Scans (AI-REPORT Study) | Thoracic Diseases, respiratory system disorder | Recruiting | Not applicable | 2026-06-09 | NCT07634861 | |
| Online Adaptive Radiotherapy for Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-01-08 | NCT06562166 | |
| The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China | basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, parkinsonian disorder | Recruiting | Not stated | 2025-10-02 | NCT03649503 | |
| Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction | Acute Myocardial Infarction (AMI); Percutaneous Coronary Intervention (PCI) | Not yet recruiting | Phase 4 | 2025-09-04 | NCT07153744 | |
| The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 | 2025-01-13 | NCT06770296 | |
| The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2024-02-12 | NCT06254690 | |
| Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN | myelodysplastic/myeloproliferative neoplasm | Recruiting | Phase 2 | 2023-04-18 | NCT05817955 |